Clinical Trial: Efficacy, Safety, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Study of Ravulizumab in Chinese Adult Patients with NMOSD (China)

Posted On: 2026-08-11

China, Aug. 11 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Efficacy, Safety, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Study of Ravulizumab in Chinese Adult Patients with NMOSD'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600129539

Registration Time: 2026/08/06

Type: Interventional study

Primary Sponsor: Huashan Hospital, Fudan University

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=333810

Published by HT Digital Content Services with permission from Health Daily Digest....

Click here to read full article from source

To read the full article or to get the complete feed from this publication, please Contact Us.

Exclusive

Category

Source

Publication

Location

Clinical Trial: Efficacy, Safety, Pharmacokinetic, Pharmacodynamic, and Immunogenicity Study of Ravulizumab in Chinese Adult Patients with NMOSD (China)